Key facts
- This page summarizes Christopher Gibson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 8 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 14 Jan 2022, 19:42.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Sale
Sale
Conversion of derivative security
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Gift
Conversion of derivative security
Conversion of derivative security
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Represents the conversion of Class B Common Stock into Class A Common Stock.
Footnote F2
Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $13.80 to $14.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F4
This transaction was executed in multiple trades at prices ranging from $14.80 to $15.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F5
This transaction was executed in multiple trades at prices ranging from $13.09 to $14.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F6
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
Footnote F7
The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F8
The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
Footnote F9
The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
Footnote F10
The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.